Medical Technology

CORE Diagnostics Enthralls Scientific Community with New Findings

  •  Esteemed oncologists from all over India came together at the Sixth Annual Conference of Young Radiation Oncologists of India, an event was organized at Taj — Vivanta, Dwarka, New Delhi.
  • New findings presented by CORE Diagnostics in the field of molecular biology and central nervous system diagnosis for treating cancer captured the attention of the scientific community.
  • Around 300 oncologists of from 16 organizations participated at the 3-day event exchanging ideas on various concepts in oncology, especially recurrences of various tumors and the role of re-irradiation in their management.

As the world finds its way in exploring newer possibilities of treating cancer, at home young Indians are shaping their own path. At a scientific convention on radiation oncology, which is a medical specialty involving the use of radiation therapy as a treatment method to cure cancer, young oncologists across the country came together to discuss latest observations.

However, it was the findings of Dr. Kunal Sharma, from CORE Diagnostics, which invoked most interest and curiosity of the scientific community present at the Sixth Annual Conference of Young Radiation Oncologists of India.

Packed with science, humor and art, the presentation given by Dr. Kunal Sharma, who is a leading pathologist at CORE Diagnostics, talked about the new developments in understanding the central nervous system (CNS) through molecular biology, an advanced medical diagnostic technique used to diagnose, classify and treat CNS tumors. “To treat various kinds of cancers, microscopic examinations of tissues especially in CNS tumors have a limited value. CNS tumors can widely be grouped today based on known mutations in various genes. Also, there are known inherent biological differences in the same tumor known as tumor heterogeneity. The subgrouping of CNS tumors in the latest classification and their treatment is largely based on these molecular subgroups. Our findings and latest guidelines stress the need for using histology as a guide to further molecular testing to properly diagnose and classify CNS tumors so that they can be appropriately prognosticated and treated. They also stress that whether a test is required or recommended for diagnosis is entirely dependent on the biological property of the tumor or whether the biomarker is diagnostic, prognostic, or predictive.”

Dr. Sharma concluded the talk by highlighting the upcoming concept in integrating genomics to predict response to radiation via the genomic-adjusted radiation dose (GARD) score. This score brings to the forefront the fact that a higher radiation dose does not necessarily have the better therapeutic effect in different kinds of tumors and in the same kind of tumor in different patients. There are various genes, which predict the radio-sensitivity of a tumor in a patient, thereby guiding treatment protocols and personalizing the treatment given to different patients.  The most important conclusion is that these molecular tests are to be taken as an integrated next step to histological diagnosis and not a replacement for it.

At the convention which was attended by over 300 doctors, scientists, and oncology experts from over around 16 esteemed organizations in India, Dr. Sharma pushed for hierarchy of testing, highlighted the need to explore the reasons for performing and not performing a molecular test, and called for combining the surgical pathology report with the molecular report wherever feasible, to have a complete, integrated diagnosis at one place.

“We are invested in bridging the gap between Indian diagnostic industry and the world. Of many other fields, we have focused on molecular diagnostics heavily to find a better therapy to treat cancer. The environment of research in India is just warming up, and our regular efforts are directed towards bringing the world to India. These findings would be of significant effect in treating breast cancer, lung cancer, and pancreatic cancer”, said Zoya Brar, Founder & MD, CORE Diagnostics.

With India recording one of the highest numbers of cancer cases, sharing of knowledge on such platforms gives better visibility of how India is planning to cope with the increasing incidence of various types of cancers.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top